Consistent with the strategic plan presented at the beginning of the year: Leumi continues to show high double-digit returns – and a net income of NIS 2.4 billion ($646 million) in the first quarter of 2025

— Return on equity in Q1 2025: 15.4% — Net income increased by 12% compared to the corresponding period last year* — Capital return in Q1 2025 amounts toNIS 961 million ($258 million), out of which NIS 721 million ($194 million) is cash dividend and the remainder is share buyback – which together constitute 40% […]

Basilea announces commercial availability of antibiotic Zevtera(R) (ceftobiprole) in the United States

(SWX:BSLN.SW),(Boerse Stuttgart – Freiverkehr:BSLN),(Boerse Berlin – Freiverkehr:BSLN),(Boerse Frankfurt – Freiverkehr:BSLN),(Boerse Muenchen – Freiverkehr:BSLN), Allschwil, Switzerland, May 20, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that its antibiotic Zevtera(R) (ceftobiprole medocaril for injection) is now commercially available

Basilea announces commercial availability of antibiotic Zevtera(R) (ceftobiprole) in the United States

Basilea announces commercial availability of antibiotic Zevtera(R) (ceftobiprole) in the United States GlobeNewswire May 20, 2025 Allschwil, Switzerland, May 20, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that its antibiotic Zevtera(R) (ceftobiprole medocaril for injection) is

SPOT-MAS Lung: AI-Powered Blood Test Brings New Hope to High-Risk Non-Smokers in Asia

In a bold step toward equitable cancer care, Gene Solutions introduces SPOT-MAS Lung, a next-generation blood-based test powered by artificial intelligence (AI) and multi-omics analysis. Designed with lung-specific features, SPOT-MAS Lung may offer a promising approach for earlier detection in Asia-especially among asymptomatic individuals who are often missed by traditional screening, or patients with symptoms

Dionisio Gutiérrez Meets with Asturian Media Ahead of the VI Citizen Convention

This media tour is part of the agenda leading up to the VI Citizen Convention As part of the lead-up to the VI Citizen Convention, which will take place on Thursday, May 22 at the Campoamor Theater in Oviedo, Asturias, Dionisio Gutiérrez, president of Fundación Libertad y Desarrollo, embarked on an intensive media tour aimed

Infrastructure Boom at Risk: New Data Warns of Budget Creep, Inefficiencies and Costly Rework in the Construction Sector

— 41% of global leaders in architecture, engineering, construction and operations see infrastructure as the top growth area for design and construction. — Yet, 56% say client changes and scope creep are the primary causes of costly project rework. — Although the construction industry is making progress in digitization, technology integration and adoption still emerged

Wego and Azerbaijan Tourism Board Partner to Showcase Azerbaijan’s All Season Allure to MENA Travelers

Wego, the number 1 travel app and the largest online travel marketplace in the Middle East and North Africa (MENA), is proud to announce its latest strategic partnership with the Azerbaijan Tourism Board, spotlighting Azerbaijan as an all-season destination tailored for curious, culture-driven, and wellness-seeking travelers from the MENA region. https://mma.prnewswire.com/media/2688303/Wego.jpg With an increasing demand

VERAXA Biotech Appoints Rick Austin as Chief Scientific Officer

VERAXA Biotech AG (“VERAXA”), an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition Corp. (NASDAQ:VACH, “Voyager”), announced today the appointment of Rick Austin, Ph.D. as Chief Scientific Officer, effective May 1st. Dr. Austin brings more than 25 years of leadership across oncology discovery and early development and will

VERAXA Biotech Appoints Rick Austin as Chief Scientific Officer

VERAXA Biotech Appoints Rick Austin as Chief Scientific Officer Industry Veteran to Support Acceleration of Key Pipeline Projects and Novel BiTAC Antibody Formats Towards Clinical Studies GlobeNewswire May 20, 2025 VERAXA Biotech AG (“VERAXA”), an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition Corp. (NASDAQ:VACH, “Voyager”), announced today

MediThinQ Enters China Through Strategic Partnership with Sinopharm, Making Wearable Surgical Displays a Reality in Operating Theatres

MediThinQ, the South Korean company specialising in wearable extended reality (XR) surgical displays, announced a strategic partnership with Sinopharm, a state-owned Chinese healthcare giant and the largest pharmaceutical and medical distribution company in China. This partnership – which includes an exclusive distribution agreement for MediThinQ's flagship product, Scopeye, in China – marks MediThinQ's entry into

Scroll to Top